RGNX
Regenxbio Inc
NASDAQ: RGNX · HEALTHCARE · BIOTECHNOLOGY
$8.97
+6.79% today
Updated 2026-04-30
Market cap
$452.17M
P/E ratio
—
P/S ratio
2.65x
EPS (TTM)
$-3.76
Dividend yield
—
52W range
$7 – $16
Volume
0.8M
Regenxbio Inc (RGNX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-3.01M | $-2.40M | $-22.52M | $-48.56M | $-57.99M | $104.65M | $-107.70M | $-54.06M | $218.88M | $-207.49M | $-218.41M | $-173.13M | $-123.96M |
| Capital expenditures | $0.00 | $522000.00 | $522000.00 | $8.15M | $7.16M | $13.28M | $11.72M | $26.87M | $84.17M | $30.72M | $9.96M | $2.44M | $2.41M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $319000.00 | $2.92M | $7.03M | $10.61M | $16.64M | $26.85M | $31.95M | $38.81M | $40.79M | $40.27M | $38.46M | $34.56M |
| Free cash flow | $-3.01M | $-2.92M | $-23.04M | $-56.71M | $-65.15M | $91.37M | $-119.42M | $-80.93M | $134.70M | $-238.21M | $-228.37M | $-175.56M | $-126.38M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | $-29.28M | $21.82M | $29.73M | $-5.77M | $268.91M | $7.48M | — | — | — | — |